Back to News
Nov 10, 2025 4:00 PM

AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial

AstraZeneca Plc (NASDAQ:AZN) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as well as safety and tolerability in participants with resistant hypertension.

• AZN is approaching key resistance levels. Find out why here.

The company released topline data in October.

The trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average SBP compared with placebo ...